Results 241 to 250 of about 482,563 (349)

Activation of brain regions vulnerable to Alzheimer's disease: The effect of mild cognitive impairment [PDF]

, 2005
Sterling C. Johnson, Taylor W. Schmitz, Chad H. Moritz, M. Elizabeth Meyerand, Howard A. Rowley, Andrew L. Alexander, Kelly Hansen, Carey E. Gleason, Cynthia M. Carlsson, Michele L. Ries, S. Asthana, Kewei Chen, Eric M. Reiman, Gene E. Alexander   +13 more
openalex   +1 more source

Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Alzheimer's disease (AD), characterized by β‐amyloid (Aβ) plaques and neurofibrillary tangles, is the leading cause of dementia globally. Donanemab is a humanized immunoglobulin G1 in development as a treatment to slow AD progression. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PKs), and immunogenicity of donanemab
Junyu Xu, Nan Zhao, Yihui Wang, Ivelina Gueorguieva, Chenxi Qian, Yimin Cui   +5 more
wiley   +1 more source

A systematic review and meta-analysis of pteridines in mild cognitive impairment and Alzheimer's disease. [PDF]

BMC Geriatr
Mangoni AA, Zinellu A.
europepmc   +1 more source

Pharmacotherapy of mild cognitive impairment

, 2004
Serge Gauthier
openalex   +1 more source

Fast decay of iconic memory in observers with mild cognitive impairments [PDF]

, 2005
Zhong‐Lin Lu, James Neuse, Stephen Madigan, Barbara Anne Dosher   +3 more
openalex   +1 more source

Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed‐Dose Combination Versus Single‐Component Tablets in Healthy Korean Males

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A fixed‐dose combination (FDC) tablet formulation of donepezil/memantine (10/20 mg) was developed to improve medication compliance in patients with Alzheimer's disease (AD). This study compared the pharmacokinetic (PK) characteristics and safety profiles of an FDC formulation (donepezil/memantine [10/20 mg]) and single components (SCs) of ...
Minkyu Choi, Byung Hak Jin, Do Hoon Keum, Kyoung Hoon Mo, Min Soo Park, Juhwan Lee, Sungjin Park, Choon Ok Kim   +7 more
wiley   +1 more source

Neuropsychological methods in mild cognitive impairment

, 2004
Valérie Hahn‐Barma, Céline Chamayou, Christina Rogan, Marie Sarazin, Bruno Dubois   +4 more
openalex   +1 more source

PET Network Abnormalities and Cognitive Decline in Patients with Mild Cognitive Impairment [PDF]

, 2005
Davangere P. Devanand, Christian Habeck, Matthias H. Tabert, Nikolaos Scarmeas, Gregory H. Pelton, James R. Moeller, Brett D. Mensh, Tyler Tarabula, Ronald L. Van Heertum, Yaakov Stern   +9 more
openalex   +1 more source

Examining the Financial Impact of Biodiversity‐Related Reputational Disasters

Corporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT This research investigates the reaction of financial markets to biodiversity‐related corporate events, utilising an EGARCH model to assess the implications on stock returns and volatility. Results reveal that markets significantly respond to these events, demonstrating heightened sensitivity and volatility that underscore the financial ...
Erdinc Akyildirim, Shaen Corbet
wiley   +1 more source

Regulatory aspects of mild cognitive impairment: toward a harmonized perspective

, 2004
Peter J. Whitehouse
openalex   +1 more source